Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cadence Design Systems Inc (CDNS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Cadence Design Systems IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Cadence Design Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Cadence Design Systems Inc trades at $326.51 (market cap $90.20B), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: Cadence Design Systems Inc is far larger — about 5.5× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.

CDNSNBIX
Market Cap
$90.20B$16.46B
Sector
TechnologyHealth
52-Week High
$416.39$185.50
52-Week Low
$265.66$123.10
Enterprise Value
$91.41B$16.48B

Returns comparison

Trailing returns across standard periods

About Cadence Design Systems Inc

Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.

Read more on CDNS

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX